Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and prog

Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating

The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While t

Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones a

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.80) per share which beat the analyst consensu

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief

– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise

Avidity Partners Management LP lifted its holdings in shares of Immunic, Inc. (NASDAQ: IMUX) by 42.6

NEW YORK, July 9, 2026 /PRNewswire/ --  Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology co

NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology co

Prediction market traders are pricing a 78% chance that SpaceX closes its first day of trading above

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consorti

Immunic, Inc.(NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel o

– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disabilit

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consorti

FTSE 100 up 13 points at 10,505 Asian and US tech stocks drive new global markets to all-time highs 

Amazon.com Inc (NASDAQ:AMZN) is significantly underappreciated by Wall Street as artificial intellig

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief

– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® –

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its CEO a

Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik

Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik

B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers t

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies fo

Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry

– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played

Immunic (NASDAQ:IMUX) reported quarterly losses of $(1.08) per share which missed the analyst consen

Top Wall Street analysts changed their outlook on top names. See all rating changes at https://www.b

HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and r

Immunic appoints Michael Panzara as CMO, granting inducement equity award as he takes charge of clin

Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to

Stifel analyst Paul Matteis initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and ann

Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzing

Guggenheim analyst Yatin Suneja initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and

Wall Street analysts changed outlook on top names: BTIG cut CRWD PT, Piper Sandler cut BSY PT, RBC C

HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and l

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.07) per share which beat the analyst consensu

Immunic stock surges on oversubscribed private placement raising $400 million to accelerate commerci

Immunic Inc (NASDAQ:IMUX) is surging Friday after the late‑stage biotech announced a private placeme

D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the

HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and

Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Infla